These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35049682)

  • 21. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
    Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
    Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
    Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
    Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
    Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
    Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
    Nizam E; Erin N
    Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis.
    Guan L; Yuan S; Ma J; Liu H; Huang L; Zhang F
    Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36629320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.
    Momen Razmgah M; Ghahremanloo A; Javid H; AlAlikhan A; Afshari AR; Hashemy SI
    Mol Biol Rep; 2022 Oct; 49(10):9307-9314. PubMed ID: 35960409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
    Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
    Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
    Matalińska J; Świć A; Lipiński P; Misicka A
    Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
    Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
    Nizam E; Köksoy S; Erin N
    Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-
    Javid H; Afshari AR; Zahedi Avval F; Asadi J; Hashemy SI
    Biomed Res Int; 2021; 2021():8808214. PubMed ID: 34926694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging targets for cough therapies; NK1 receptor antagonists.
    Badri H; Smith JA
    Pulm Pharmacol Ther; 2019 Dec; 59():101853. PubMed ID: 31622673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma.
    Ebrahimi S; Mirzavi F; Hashemy SI; Khaleghi Ghadiri M; Stummer W; Gorji A
    Biofactors; 2023; 49(4):900-911. PubMed ID: 37092793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
    Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
    Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
    Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
    AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
    Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
    Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
    Dikmen M; Gökhaner G; Cantürk Z
    Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.